Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics Oxford, UK, 14 July 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’) – a pioneering biotechnology company unlocking the therapeutic potential of the regulatory genome through its proprietary 3D genomics platform – […]
Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies Oxford, UK, 16 February 2026 – Nucleome Therapeutics […]
A multi-billion dollar collaboration between Prime Medicine Inc. and Bristol-Myers Squibb brings this important technology closer to patients. At the end of 2023, the FDA already approved Casgevy (exagamglogene autotemcel), developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals for sickle cell disease and beta thalassemia, and bluebird bio’s Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease. […]
Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, has over 12 […]
Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]
